Company / Operating Cash Flow
Adaptive Biotechnologies Corp Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$46.0M
FY2025
5-year range
-$192.7M / -$46.0M
FY2021-FY2025
Trend
+51.7%
vs FY2024
Sector context
#94 of 216
Health Care
What the data says
At -$46M, Adaptive Biotechnologies Corp's operating cash flow ranks #94 of 216 in the Health Care sector. Operating Cash Flow has increased for 4 consecutive years, from -$193M in FY2021 to -$46M in FY2025.
Based on SEC 10-K filings.
-$46M in FY2025.
Improved from -$156M to -$46M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#94 of 216 in Health CareTop 44% of 216This company -$46.0M Sector average $659.0M
▼
-107.0% below sector average
Key checks
Key Insights
- Adaptive Biotechnologies Corp's operating cash flow has grown for 4 consecutive years.
- In FY2025, operating cash flow increased 51.7% year-over-year.
- Ranks #94 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -1.45 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$46.0M | +51.7% |
| FY2024 | -$95.2M | +39.1% |
| FY2023 | -$156.3M | +15.0% |
| FY2022 | -$183.9M | +4.6% |
| FY2021 | -$192.7M | -28.8% |
| FY2020 | -$149.7M | -172.9% |
| FY2019 | $205.4M | +736.7% |
| FY2018 | -$32.3M | +7.5% |
| FY2017 | -$34.9M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026